Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.93USD
7:10pm GMT
Change (% chg)

$-0.03 (-0.50%)
Prev Close
$5.96
Open
$5.95
Day's High
$6.01
Day's Low
$5.83
Volume
8,087
Avg. Vol
24,599
52-wk High
$11.26
52-wk Low
$4.03

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: --
Market Cap(Mil.): $241.40
Shares Outstanding(Mil.): 37.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

15 Nov 2017

BRIEF-Foamix Q2 loss per share $0.44

* Foamix reports second quarter 2017 financial results and provides business update

08 Aug 2017

BRIEF-Foamix says expects to report top-line results from study FX2017-22 by mid-2018​

* Foamix announces dosing of first patient in third phase 3 acne study for minocycline foam fmx101

03 Aug 2017

BRIEF-Foamix Pharmaceuticals appoints David Domzalski as CEO

* Foamix Pharmaceuticals appoints David Domzalski as chief executive officer

29 Jun 2017

Earnings vs. Estimates